Psilocybine services in Oregon: a call for awareness among clinical toxicologists.
Clinical toxicology (Philadelphia, Pa.) March 1, 2023 DOI: 10.1080/15563650.2023.2182664 via PubMed
Summary
AI-generated from the abstractOregon's 2023 laws regulating psilocybine services require licensed facilities and trained facilitators for supervised sessions. A clinical toxicologist's commentary reviews the final rules, highlighting issues such as non-clinical facilitators' scope of practice, prevention and management of adverse drug reactions, and toxicological uncertainties about dosing for people with mental health or other medical conditions. The commentary also addresses common misperceptions about the program and outlines challenges clinical toxicologists may face as psilocybine legislative reform advances across the United States.
Study at a glance
| Characteristics | Commentary Peer reviewed |
|---|---|
| Intervention | Psilocybine |
| Keywords | Psilocybine Adverse event Toxicology Psychedelics hallucinogens Entheogens |
| Citations | 6 |
| Key finding | Oregon's regulatory framework for psilocybine services raises unresolved questions about facilitator scope, adverse event management, and dosing for medically vulnerable populations. |
Abstract
In 2023, Oregon enacted laws regulating the manufacture and use of psilocybine products in licensed facilities for supervised sessions with trained facilitators. This commentary summarizes the final rules for psilocybine services in Oregon, and provides perspectives from a clinical toxicologist on some of the issues that may arise. These include the scope of practice for non-clinical facilitators, prevention and management of adverse drug reactions, and toxicological uncertainties with regards to dose considerations for people with mental health and other medical conditions. This commentary addresses some common misperceptions relating to the program, and provides perspective on some of the challenges that clinical toxicologists may encounter as legislative reform initiatives for psilocybine move forward throughout the United States.